Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Plain-language title generated from the registry record
Registry title: A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Key facts
- Where
- Baia Mare, Baloteşti, Brasov, Bucharest, Iași, Maramureș, Oradea, Ploiesti, Satu Mare, Sibiu, Targu Mures, Târgu Mureş, and Timisoara, RomaniaSee the 20 sites
- Phase
- Phase 3
Where in Romania
- CMI Cardiologie - Dr. Mercea Corina DeliaBaia Mare, RomaniaTaking people
- Spitalul Clinic De Urgenta Prof Dr Agrippa IonescuBaloteşti, RomaniaTaking people
- Centrul Medical De Diagnostic Si Tratament Ambulator Neomed S.R.L.Brasov, RomaniaTaking people
- CRN Clinical Research Network S.R.L.Bucharest, RomaniaTaking people
- Diabet Med S.R.L.Bucharest, RomaniaTaking people
- Easydiet S.R.L.Bucharest, RomaniaTaking people
- Lotus Med S.R.L.Bucharest, RomaniaTaking people
- Nicodiab S.R.L.Bucharest, RomaniaTaking people
- Nutrilife S.R.L.Bucharest, RomaniaTaking people
- Cardiomed S.R.L.Iași, RomaniaTaking people
- Cabinet Medical Individual Diabet, Nutritie, Boli Metabolice Dr. Pop LaviniaMaramureș, RomaniaTaking people
- Diabdana S.R.L.Oradea, RomaniaTaking people
- Dianutrilife Medica S.R.L.Ploiesti, RomaniaTaking people
- Clinica Korall S.R.L.Satu Mare, RomaniaTaking people
- Gensan S.R.L.Sibiu, RomaniaTaking people
- Dentosim-Queen S.R.L.Targu Mures, RomaniaTaking people
- CMI Dr Podoleanu CristianTârgu Mureş, RomaniaTaking people
- Mediab S.R.L.Târgu Mureş, RomaniaTaking people
- Cabinet Medical Dr Geru S.R.L.Timisoara, RomaniaTaking people
- Medicali's S.R.L.Timisoara, RomaniaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07241390EU 2025-523123-22-00
- Record updated
- 4 November 2026
- Original description
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.Read full original descriptionShow less
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
Inclusion: Have established ASCVD and/or CKD.
Exclusion: Have had a major heart condition within 60 days prior to screening; Have type 1 diabetes; Have New York Heart Association Functional Classification Class IV heart failure.